<DOC>
	<DOCNO>NCT03093129</DOCNO>
	<brief_summary>This Phase II randomize , double-blind , placebo-controlled trial neoadjuvant artesunate give orally dose 200 mg day 14 day patient histologically confirm Stage II/III colorectal cancer ( CRC ) await surgical treatment curative intent .</brief_summary>
	<brief_title>Safety Effectiveness Study Pre-operative Artesunate Stage II/III Colorectal Cancer ( NeoART-V )</brief_title>
	<detailed_description>Colorectal cancer ( CRC ) third common cancer worldwide represent significant health care burden incidence one million new case per year . In Vietnam , Colorectal cancer third common cause cancer death men fourth woman . Artesunate safe effective antimalarial evidence anticancer property across range cancer cell line . Results pilot feasibility study colorectal cancer patient UK show artesunate safe well tolerate . These finding provide basis Phase II clinical trial investigate effect neoadjuvant artesunate progression free survival overall survival Stage II/III Colorectal Cancer Vietnamese Patients . Artesunate give orally dose 200 mg day 14 day patient histologically confirm Stage II/III colorectal cancer ( CRC ) await surgical treatment curative intent .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Artesunate</mesh_term>
	<mesh_term>Artemisinins</mesh_term>
	<criteria>Aged 18 Histologically proven single primary site colorectal adenocarcinoma Stage II/III colorectal cancer plan surgical resection clinical indication neoadjuvant preoperative chemotherapy/chemoradiation therapy WHO performance status 0,1 2 Adequate full blood count : White Cell Count ( WCC ) &gt; 3.0 x 109 /l ; Platelets &gt; 100 x 109/l ; Haemoglobin ( Hb ) &gt; 8g/dL Adequate renal function : Glomerular Filtration Rate &gt; 30ml/min CockcroftGault formula Adequate hepatobiliary function : Bilirubin &lt; 3 x Upper limit normal Female participant child bear potential must negative pregnancy test &lt; 72 hour prior initiate study intervention agree avoid pregnancy use contraceptive precaution 6 week last dose study treatment intervention Male participant partner childbearing potential must agree use contraceptive precaution 6 week last dose study treatment intervention Patient able willing provide write , inform consent study Contraindication use artesunate due hypersensitivity Pregnancy lactation History immunosuppression History hear balance problem Weight &lt; 42 kg &gt; 110 kg Other plan intervention , apart Vietnamese standard care Any malignant disease diagnosis within precede 2 year exception nonmelanomatous skin cancer carcinoma situ Lactose intolerance</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>